Chargement en cours...
Cost–Utility Analysis of Dapagliflozin as an Add-On to Standard Treatment for Patients with Type 2 Diabetes and High Risk of Cardiovascular Disease in Thailand
INTRODUCTION: Diabetes treatment has incurred financial burden. We examined the cost–utility of adding dapagliflozin to the standard treatment for treating type 2 diabetes (T2DM) with cardiovascular risk in a Thai context. METHODS: A two-part model, decision tree and Markov models, was developed to...
Enregistré dans:
| Publié dans: | Diabetes Ther |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Healthcare
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8266922/ https://ncbi.nlm.nih.gov/pubmed/34106450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-021-01088-w |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|